Cargando…

Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens

BACKGROUND: programmed death-ligand 1 (PD-L1) is a ligand for the inhibitory programmed cell death protein 1 (PD-L1), which are targeted by several anti-PD-1 and PD-L1 drugs for lung cancer treatment. In clinical practice, many lung cancer cases only have cytology samples available to test PD-L1. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Huihong, Bratton, Laura, Nead, Michael, Russell, Donna, Zhou, Zhongren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319045/ https://www.ncbi.nlm.nih.gov/pubmed/30662515 http://dx.doi.org/10.4103/cytojournal.cytojournal_2_18

Ejemplares similares

Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples
por: Muggilli, Michael, et al.
Publicado: (2021)

Formalin fixation for optimal concordance of programmed death‐ligand 1 immunostaining between cytologic and histologic specimens from patients with non–small cell lung cancer
por: Koomen, Bregje M., et al.
Publicado: (2020)

Automated Immunostaining Platform in Cytology
por: Sharma, Shelly, et al.
Publicado: (2021)

Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms
por: Matsumoto, Kazuyuki, et al.
Publicado: (2022)

PD−L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2021)

False‐negative programmed death‐ligand 1 immunostaining in ethanol‐fixed endobronchial ultrasound‐guided transbronchial needle aspiration specimens of non‐small‐cell lung cancer patients
por: Koomen, Bregje M, et al.
Publicado: (2021)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Immunostaining of p16(INK4a)/Ki-67 and L1 Capsid Protein on Liquid-based Cytology Specimens Obtained from ASC-H and LSIL-H Cases
por: Byun, Seung Won, et al.
Publicado: (2013)

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens
por: Saito, Akira, et al.
Publicado: (2020)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens
por: Bubendorf, Lukas, et al.
Publicado: (2020)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

A comparison of cytological and histopathological findings and role of immunostains in the diagnosis of soft tissue tumors
por: Beg, Shaham, et al.
Publicado: (2012)

Correlation Study on the Expression of INSR, IRS-1, and PD-L1 in Nonsmall Cell Lung Cancer
por: Ting, Ma, et al.
Publicado: (2022)

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)

Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non–Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience
por: Sayman Gokal, Elif, et al.
Publicado: (2022)

Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules
por: Teshima, Masanori, et al.
Publicado: (2019)

Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women()
por: Jiang, Yunhui, et al.
Publicado: (2019)

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters
por: Silva, Manuel A., et al.
Publicado: (2018)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer
por: Qu, Yanli, et al.
Publicado: (2021)

Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer
por: Mansour, Mohammed S. I., et al.
Publicado: (2021)

Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
por: Satturwar, Swati, et al.
Publicado: (2022)

High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
por: Hagmeyer, Lars, et al.
Publicado: (2021)

Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab
por: Nakayama, Shingo, et al.
Publicado: (2018)

Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy
por: Zhao, Jing, et al.
Publicado: (2017)

Machine Learning Classifies Ferroptosis and Apoptosis Cell Death Modalities with TfR1 Immunostaining
por: Jin, Jenny, et al.
Publicado: (2022)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma
por: Hoffmann, Lucas Grecco, et al.
Publicado: (2021)

Value and Limits of Routine Histology Alone or Combined with Glutamine Synthetase Immunostaining in the Diagnosis of Hepatocellular Adenoma Subtypes on Surgical Specimens
por: Bioulac-Sage, Paulette, et al.
Publicado: (2013)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Improvization of conventional cytology by centrifuged liquid-based cytology in oral exfoliative cytology specimen
por: Nambiar, Shwetha, et al.
Publicado: (2016)

The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer
por: Egger, Eva K., et al.
Publicado: (2023)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pal3pjs5kemetnbh84hijjvkdm